United States ($) USD
Austria (€) EUR
Belgium (€) EUR
Denmark (DKK) DKK
Finland (€) EUR
France (€) EUR
Germany (€) EUR
Ireland (€) EUR
Japan (¥) JPY
Luxembourg (€) EUR
Netherlands (€) EUR
Norway (NOK) NOK
Sweden (SEK) SEK
Switzerland (CHF) CHF
United Kingdom (£) GBP
- Other Names
- Interleukin-17A, Cytotoxic T-lymphocyte-associated antigen 8, cytotoxic T-lymphocyte-associated serine esterase 8, CTLA-8, IL-17
- Ave. Rating
- Submit a Review
- Product Citations
- publications
-
Induction of IL-6 in human dermal fibroblast by Cell-Vive™ GMP Recombinant Human IL-17A.
| Cat # | Size | Price | Quantity | Save | ||
|---|---|---|---|---|---|---|
| 570514 | 25 µg | ¥162,800 | ||||
| 570516 | 100 µg | ¥407,000 | ||||
IL-17A was initially identified from a subtracted cDNA library between closely related murine lymphoid cells called CTLA-8, and share 58% homology with an open reading frame of the T-lymphotropic Herpesvirus Samirii virus (viral IL-17). IL-17A belongs to a family of cytokines, which has five members; designated IL- 17A-F. IL-17 is expressed by a unique lineage of CD4 T cells (Th17) that develop in response to IL-23, in particular under conditions in which Th1 and Th2 development are suppressed. IL-17A shares the greatest homology (55%) with IL- 17F. Both IL-17A and IL-17F are produced by Th17 cells. IL-17A and IL-17F can exist either as IL-17A homodimers and IL-17F homodimers or as IL-17A-IL-17F heterodimers. IL-17 is a key mediator of autoimmune disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, asthma, and plays a role in host defense.
Product DetailsBioLegend Cell-Vive™ GMP Recombinant proteins are manufactured and tested in accordance with USP Chapter 1043, Ancillary Materials for Cell, Gene and Tissue-Engineered Products and Ph. Eur. Chapter 5.2.12 in a dedicated GMP facility compliant with ISO 13485:2016. Specifications and processes include:
- Low endotoxin level (≤ 0.1 EU/μg)
- Purity (≥ 95% or higher)
- Bioburden testing
- Mycoplasma testing
- Batch-to-batch consistency
- Vendor qualification
- Raw material traceability and documentation
- Documented procedures and employee training
- Equipment maintenance and monitoring records
- Lot-specific certificates of analysis
- Quality audits per ISO 13485:2016
- QA review of released products
Product Details
- Source
- Human IL-17A, amino acids Ile20-Ala155 (Accession # NM_002190) was expressed in E. coli.
- Molecular Mass
- The 137 amino acid N-terminal methionylated recombinant protein has a predicted molecular mass of 16 kD. This protein exists as a disulfide-linked homodimer. The DTT-reduced protein migrates at approximately 16 kD by SDS-PAGE. The non-reduced protein migrates as a homodimer, at approximately 28 kD by SDS-PAGE.
-
N-terminal
Sequence Analysis - Met-Ile-Val-Lys-Ala-Gly-Ile-Thr-Ile-Pro
- Purity
- ≥ 95%, as determined by Coomassie stained SDS-PAGE
- Formulation
- 0.1 μm filtered protein solution is in 10 mM Sodium Phosphate buffer, 300 mM NaCl, pH 7.2.
- Endotoxin Level
- Less than or equal to 0.1 EU per μg of protein as determined by LAL method.
- Residual Host Cell Protein Content
- ≤ 0.500 ng/μg by ELISA
- Concentration
- 25 μg & 100 μg sizes are bottled at 0.5 mg/mL
- Storage & Handling
- Unopened vials can be stored at ≤ -70°C for 4 years, ≤ -20°C for 6 months, and between 2°C and 8°C for 2 weeks. Aliquots can be stored between -20°C to -70°C for 3 months and between 2°C and 8°C for 1 week. For maximum results, quick spin vial prior to opening. Stock solutions can also be prepared at 50 - 100 μg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% endotoxin-free BSA or HSA can be added when preparing the stock solution. Avoid repeated freeze/thaw cycles.
- Activity
- Cell-Vive™ GMP Recombinant Human IL-17A induces IL-6 production in human neonate dermal fibroblasts in a dose-dependent manner. The ED50 for this effect is 0.06 – 0.36 ng/mL.
- Application
-
Bioassay
- Application Notes
-
BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are verified in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech-BioLegend@revvity.com.
-
Application References
(PubMed link indicates BioLegend citation) -
- Crawford MP, et al. 2020. Proc Natl Acad Sci U S A. 117:19408. PubMed
- Kakiuchi N, et al. 2020. Nature. 577:260-265. PubMed
- Akaki K, et al. 2021. Elife. 10:e71966. PubMed
- Luo J, et al. 2019. Mediators Inflamm. 2019:9050965. PubMed
- Luo X, et al. 2021. Neuron. 109:2691. PubMed
- Jaeger N, et al. 2020. Cell Rep. 33:108331. PubMed
- Disclaimer
-
BioLegend Cell-Vive™ GMP Recombinant proteins are for research use only. Suitable for ex vivo cell processing. Not for injection or diagnostic or therapeutic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.
Antigen Details
- Structure
- Cytokine
- Ligand/Receptor
- IL-17A signals through a heteromeric receptor composed of IL-17RA and IL-17RC.
- Bioactivity
- Human IL-17A induces IL-6 production in human neonate dermal fibroblasts.
- Cell Sources
- IL-17A is largely produced by activated memory T lymphocytes, CD4+ T helper cells (Th17), neutrophils, CD8(+), NK, and gamma-delta T cells.
- Cell Targets
- IL-17AR is expressed in epithelial cells, fibroblasts, B and T lymphocytes, myelomonocytic cells, bone marrow stromal cells, synovial endothelial cells and chondrocytes from arthritic patients express IL-17R.
- Antigen References
-
- Yu J, et al. 2008. Front Biosci. 13:170-177
- Toy D, et al. 2006. J. Immunol. 177:36-39
- Benghiat FS, et al. 2009. Transplant Rev. 23:11-18
- Honorati MC, et al. 2001. Rheumatology. 40:522-527
- Rouvier E, et al. 1993. J. Immunol. 150:5445-5456
- Liang SC, et al. 2007. J. Immunol. 179:7791-7799
- Ouyang W, et al. 2008. Immunity. 28:454-467
- Regulation
- IL-17A is a potent regulator of granulopoiesis and neutrophil recruitment under normal and inflammatory conditions. Organ overexpression of IL-17A increases circulating neutrophil numbers and recruitment into the organs by induction of CXCL2, IL-1β, and G-CSF. IL-17A induces CXCL1, CXCL2, CXCL5, and CXCL8 in human epithelial cells. IL-17A also cooperates with TLR ligands, IL-1 beta, and TNF alpha to enhance inflammatory reactions and stimulate production of beta-defensins and other antimicrobial peptides.
- Gene ID
- 3605 View all products for this Gene ID
- UniProt
- View information about IL-17A on UniProt.org
Follow Us